{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/warts-anogenital/management/management/","result":{"pageContext":{"chapter":{"id":"c91156c1-59d1-5b14-8f39-bf08dc3bc8f9","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 92893a71-1afb-478f-a24b-6890da0f821d --><h2>Scenario: Management</h2><!-- end field 92893a71-1afb-478f-a24b-6890da0f821d -->","summary":"Covers the management of people with anogenital warts in primary care.","htmlStringContent":"<!-- begin item 6e6288b2-52de-45a4-929f-94280f12ba72 --><!-- begin field df45ea5d-40aa-4ec0-b2f3-acbd0086a5a0 --><p>From age 13 years onwards.</p><!-- end field df45ea5d-40aa-4ec0-b2f3-acbd0086a5a0 --><!-- end item 6e6288b2-52de-45a4-929f-94280f12ba72 -->","topic":{"id":"e7a3f2d8-5f5c-5ba5-a771-18dfa2a34ece","topicId":"2ff76478-9567-414a-a850-4f9608dd4feb","topicName":"Warts - anogenital","slug":"warts-anogenital","lastRevised":"Last revised in April 2017","chapters":[{"id":"673e021d-a2fb-52b7-bcd9-3467b771a57f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ac99c8bf-87d2-52a1-8485-e38fee62d2d3","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7ee801e8-cb99-5752-81b8-62e0d1660af0","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3ca6914f-3aca-5823-b591-4de01ae58b9d","slug":"changes","fullItemName":"Changes"},{"id":"ca4c177d-14a1-5222-bb51-8c52162b0687","slug":"update","fullItemName":"Update"}]},{"id":"7970a29f-32ff-5788-992e-9a2a02fd909e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"78ac4b28-280b-5af0-9547-55357fce168f","slug":"goals","fullItemName":"Goals"},{"id":"9b223dc3-5b17-5d5e-a693-4e5c5d7f89a4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8c1c2a62-d986-55e6-9131-7eeb96cd8c26","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d5e6469f-75c7-5a1c-8dea-d31a4c066353","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d2692bb1-78d5-5ce8-a2c2-252f1f8238ca","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"43a07fd6-910a-5025-a989-3db317b8cd1c","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"98c96f9a-dadf-585b-af6c-70cfbaa769af","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7a459ab9-55fe-5d56-9c06-35b3447cf0f3","slug":"definition","fullItemName":"Definition"},{"id":"9501b6fc-6ddf-57da-b4a1-0de76a0c7c49","slug":"causes","fullItemName":"Causes"},{"id":"c22bc57c-cdd6-5330-b88f-11aa440a0bd3","slug":"transmission","fullItemName":"Transmission"},{"id":"63eca59f-4ff0-5ce0-a4cb-e893f95d6d40","slug":"prevalence","fullItemName":"Prevalence"},{"id":"67bcb534-24c1-5405-a371-00e3b3234238","slug":"complications","fullItemName":"Complications"},{"id":"9f628e4f-fe37-5c7b-b9b9-68ca563cc306","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"750b2924-a2af-5b82-9d04-8071a886ec8f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"45d6382a-5bf8-52dc-be32-eca7478a9a0d","slug":"assessment","fullItemName":"Assessment"},{"id":"126f2080-3e60-5a09-a26a-8a13d5e050ea","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"a3122ed7-4faf-52d8-8714-99ebcc69d085","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"12587369-d043-546c-adf4-e1e5572741f1","fullItemName":"Management","slug":"management","subChapters":[{"id":"c91156c1-59d1-5b14-8f39-bf08dc3bc8f9","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"f5a42760-c0e3-56e3-b935-d180d409a30e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ed0173f4-aefc-569f-81f2-19df322c9290","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"913d974d-9c96-5914-836f-e8e7f72f78b3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"35560bdc-50e2-5351-9d97-40d6da9f9c18","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"813cc37b-94d6-545a-844e-7d6f84d0e99c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fc968029-b704-5091-ba16-92aeefda51c2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"81cb227a-e86d-54e1-942c-456ae8251dc2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c81502ec-60d8-5a69-ad22-46e42e704b95","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"12587369-d043-546c-adf4-e1e5572741f1","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"6a631364-79b5-5a72-9eec-e9e3d13d7942","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field bf6291c2-8e47-4f4e-b48c-3ea544ad564e --><h3>How should I manage someone with anogenital warts?</h3><!-- end field bf6291c2-8e47-4f4e-b48c-3ea544ad564e -->","summary":null,"htmlStringContent":"<!-- begin item 79057aee-da46-4dae-8535-c616094e738a --><!-- begin field f80d9139-e8f0-4ade-b75c-913edff78df4 --><ul><li><strong>If possible, refer all people with anogenital warts to a sexual health specialist. If this is not possible or acceptable, the person can be managed in primary care, if the appropriate expertise is available.</strong></li><li>Screening for co-existing sexually transmitted infections (STIs) is essential, particularly in people younger than 25 years of age and those with other genital symptoms.<ul><li>Perform a vaginal speculum examination in women.</li><li>Perform proctoscopy (where available), if there is a history of anal receptive sex.</li><li>Tracing of previous sexual partner(s) is not recommended for people with anogenital warts in the absence of other STIs.</li></ul></li><li>Only offer treatment for anogenital warts in primary care if:<ul><li>Referral to a sexual health specialist is not possible (because it is declined or unavailable) and the diagnosis of external genital warts can be confidently made.</li><li>The skills and resources to provide comprehensive assessment and treatment, as well as screening and contact tracing for other sexually transmitted infections are available.</li><li>For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/warts-anogenital/management/management/#available-treatments\">treatment</a>.</li></ul></li><li>Provide information and <a class=\"topic-reference internal-reference\" href=\"/topics/warts-anogenital/management/management/#advice\">advice</a> about anogenital warts.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/warts-anogenital/management/management/#referral\">Refer</a> where appropriate.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/warts-anogenital/management/management/#follow-up\">Follow up</a> the person if required.</li></ul><!-- end field f80d9139-e8f0-4ade-b75c-913edff78df4 --><!-- end item 79057aee-da46-4dae-8535-c616094e738a -->","subChapters":[{"id":"9dd849b2-ac99-545e-a746-3d5f8f8c88b8","slug":"available-treatments","fullItemName":"Available treatments","depth":4,"htmlHeader":"<!-- begin field 26c0c938-2316-414f-952f-a74b0110b099 --><h4>What treatments are available for anogenital warts?</h4><!-- end field 26c0c938-2316-414f-952f-a74b0110b099 -->","summary":null,"htmlStringContent":"<!-- begin item e473a2d4-a199-4770-8b9c-a74b0110af36 --><!-- begin field a624a97e-5e5c-46ed-bcb3-a74b0110b099 --><ul><li>The aim of treatment is to remove the warts.</li><li>Treatment options include:<ul><li><strong>No treatment </strong>— treatment is not always indicated, as in about 30% of people, warts disappear spontaneously within 6 months.</li><li><strong>Self-applied treatments —</strong> these cannot be used in pregnancy, are not licensed for use in children, and have a high likelihood of adverse effects. If a self-applied treatment is chosen, show the person the location of the warts and where to apply topical treatment (to reduce treatment failure owing to undertreatment):<ul><li><strong>Podophyllotoxin </strong>0.5% solution (Condyline<sup>® </sup>or Warticon<sup>®</sup>) or 0.15% cream (Warticon<sup>®</sup>) is purified extract of podophyllin. It is useful for soft, non-keratinized (non-horny), external lesions but is not licensed for anal warts. Cream may be easier to apply. Supervision by a healthcare professional is recommended when the lesion area to be treated is greater than 4 cm<sup>2</sup>. For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/warts-anogenital/management/management/#advice\">Advice</a>.</li><li><strong>Imiquimod </strong>5% cream (Aldara<sup>®</sup>) may be suitable for both keratinized (horny) <em>and </em>non-keratinized, external genital, and perianal warts but is not recommended for internal use — see <a class=\"topic-reference internal-reference\" href=\"/topics/warts-anogenital/management/management/#advice\">Advice</a>.</li><li><strong>Sinecatechins </strong>10% ointment (Catephen<sup>®</sup>). This contains green tea plant (<em>Camellia sinensis</em>) extract, primarily the catechin, epigallocatechin gallate. It is licensed for the treatment of external genital warts in people aged years or over 18 who are immunocompromised. For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/warts-anogenital/management/management/#how-to-use-sinecatechins\">Advice</a>.</li></ul></li><li><strong>Specialist application</strong> — trichloroacetic acid (TCA) 80-90% solution.</li><li><strong>Ablative methods </strong>(such as cryotherapy, excision, and electrocautery): consider if appropriately trained and resourced. These may be better for people with a small number of low-volume warts (regardless of type).</li></ul></li><li>Treatments not recommended include:<ul><li>Podophyllin — it is a herbal extract from the podophyllum plant in a 20–25% solution and is a non-standardised preparation.</li><li>5-fluorouracil.</li><li>Interferon.</li></ul></li></ul><!-- end field a624a97e-5e5c-46ed-bcb3-a74b0110b099 --><!-- end item e473a2d4-a199-4770-8b9c-a74b0110af36 -->","subChapters":[]},{"id":"7bc701c3-1de1-51d8-8627-9c403faa793c","slug":"choice-of-treatment","fullItemName":"Choice of treatment","depth":4,"htmlHeader":"<!-- begin field aec237ac-5575-48c1-9e6d-a74b0110d462 --><h4>What treatment should I offer first-line for treating anogenital warts?</h4><!-- end field aec237ac-5575-48c1-9e6d-a74b0110d462 -->","summary":null,"htmlStringContent":"<!-- begin item 22a41674-dd84-40b9-ba17-a74b0110d3af --><!-- begin field 32072fc1-5d7e-4aca-8775-a74b0110d462 --><ul><li><strong>Podophyllotoxin, imiquimod and sinecatechins are suitable for home treatment by patients.</strong> The patient should be given a demonstration on lesion finding and treatment application.</li><li>All treatments have significant failure and relapse rates (see Table 1 for more information), so the choice of treatment is dependent upon the: <ul><li><strong>Type of warts</strong> — soft non-keratinised warts respond well to podophyllotoxin, and trichloroacetic acid (TCA). Keratinised lesions may be better treated with physical ablative methods such as cryotherapy, excision, TCA or electrocautery.<ul><li>Imiquimod is suitable treatment for both keratinised and non-keratinised warts.</li></ul></li><li><strong>Number and volume of warts</strong> — a small number of low volume warts, irrespective of type, can be treated with ablative therapy, or topical treatment with podophyllotoxin.</li><li><strong>Response to previous treatments.</strong></li><li><strong>Site of lesions </strong>— podophyllotoxin cream may be easier to apply than the solution, especially for less accessible lesions.</li></ul></li><li>Other considerations include the availability, cost of treatment, the person's preference and any other co-existing medical conditions.</li></ul><p><strong>Table 1. </strong>Clearance and recurrence rates of genital wart treatments.</p><table><thead><tr><th scope=\"col\">Drug</th><th scope=\"col\">Clearance rate range*</th><th scope=\"col\">Recurrence rate range</th></tr></thead><tbody><tr><td>Imiquimod cream 5%</td><td><p>35–68%</p></td><td><p>6–26%</p></td></tr><tr><td>Podophyllotoxin solution 0.5%</td><td><p>45–83% </p></td><td><p>13–100%</p></td></tr><tr><td>Podophyllotoxin cream 0.15%</td><td>43–70%</td><td>6–55%</td></tr><tr><td>Sinecatechins ointment 10%</td><td><p>47–59%</p></td><td><p>57–11%</p></td></tr><tr><td colspan=\"3\">* Intent to treat</td></tr><tr><td colspan=\"3\"><strong>Source:</strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">Lacey, 2013</a>]</td></tr></tbody></table><!-- end field 32072fc1-5d7e-4aca-8775-a74b0110d462 --><!-- end item 22a41674-dd84-40b9-ba17-a74b0110d3af -->","subChapters":[]},{"id":"9c08dae2-6cd1-57d8-bd1c-4ae4f0a2c12a","slug":"basis-for-recommendation-6b7","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 3b900b82-ca1c-4b60-882a-937a7987e180 --><h4>Basis for recommendation</h4><!-- end field 3b900b82-ca1c-4b60-882a-937a7987e180 -->","summary":null,"htmlStringContent":"<!-- begin item 6b7f712a-6a9f-474a-a6d9-5587e395829b --><!-- begin field 3e141ab6-07a3-40b3-8203-db8feb1f708d --><h5>Management</h5><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK national guidelines on the management of anogenital warts</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BASHH, 2015</a>], joint recommendations on <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">RCGP, 2013</a>]<em>, </em>the <em>British Medical Journal</em> (BMJ) best practice guide <em>Genital warts </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BMJ Best Practice, 2016</a>], and the US Centres for Disease Control and Prevention (CDC) <em>Sexually transmitted diseases treatment guidelines</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">CDC, 2015</a>].</p><h5>Available treatments</h5><p>These recommendations are based on the British Association for Sexual health and HIV (BASHH) <em>UK national guidelines on the management of anogenital warts </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BASHH, 2015</a>], joint recommendations on <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">RCGP, 2013</a>]<em>, </em>the National Institute for Health and Care Excellence (NICE) evidence summary <em>External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">NICE, 2015</a>], the <em>British Medical Journal</em> (BMJ) best practice guide <em>Genital warts </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BMJ Best Practice, 2016</a>] and the <em>2012 European guideline for the management of anogenital warts</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">Lacey, 2013</a>].</p><ul><li><strong>No treatment option</strong><ul><li>No treatment is an option, as anogenital warts are usually benign and spontaneously disappear in 30% of people within 6 months [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BASHH, 2015</a>].</li></ul></li><li><strong>Treatments not recommended</strong><ul><li>Podophyllin (a non-standardised preparation which is not available for self-administration) and 5-fluorouracil are not recommended because of high rates of adverse effects and the availability of alternative, effective treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BASHH, 2015</a>]<strong>.</strong></li><li>CKS does not recommend the use of interferons as they are expensive, have a high rate of adverse effects and a variable response rate, and BASHH advises that they should only be used on expert advice for the management of anogenital warts [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BASHH, 2015</a>].</li></ul></li></ul><h5>Choice of treatment</h5><p>These recommendations are based on the British Association for Sexual health and HIV (BASHH) <em>UK national guidelines on the management of anogenital warts </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BASHH, 2015</a>], joint recommendations on <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">RCGP, 2013</a>]<em>, </em>the <em>British Medical Journal</em> (BMJ) best practice guide <em>Genital warts </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BMJ Best Practice, 2016</a>] and <em>Clinical evidence: Warts (genital)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">Buck, 2014</a>], a health technology assessment <em>Clinical effectiveness and cost-effectiveness of interventions for the treatment of anogenital warts: systematic review and economic evaluation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">Thurgar, 2016</a>], and a systematic review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">Werner, 2016</a>].</p><ul><li>There is very little evidence available to inform the choice of first-line treatment, as all treatments have significant failure and relapse rates [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BASHH, 2015</a>].</li><li>A health technology assessment concluded that while podophyllotoxin 0.5% solution was likely to represent a cost­ effective first­line treatment option, the overall evidence base for anogenital wart treatments was limited [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">Thurgar, 2016</a>].</li><li>A systematic review of evidence from 18 randomised controlled trials (RCTs) that looked at the efficacy of topical treatments for anogenital warts, found that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">Werner, 2016</a>]:<ul><li>Imiquimod 3.75% and 5% cream, podophyllotoxin 0.5% solution and gel and polyphenon E (sinecatechins) 10% and 15% ointment were superior to placebo.</li><li>No significant differences were detected between imiquimod 5% cream and podophyllotoxin 0.5% solution and between polyphenon E 10% and 15% ointment.</li><li>In an active-controlled trial, podophyllotoxin 0.15% cream was inferior to podophyllotoxin 0.5% solution.</li></ul></li></ul><!-- end field 3e141ab6-07a3-40b3-8203-db8feb1f708d --><!-- end item 6b7f712a-6a9f-474a-a6d9-5587e395829b -->","subChapters":[]}]},{"id":"88e3eed4-1393-5c5e-b7d5-39e87a40b974","slug":"advice","fullItemName":"Advice","depth":3,"htmlHeader":"<!-- begin field 7a369450-df78-4966-a505-80fdb0c73808 --><h3>What advice should I give someone with anogenital warts?</h3><!-- end field 7a369450-df78-4966-a505-80fdb0c73808 -->","summary":null,"htmlStringContent":"<!-- begin item 63ed9def-1b0f-401f-b24e-5193382f1ba1 --><!-- begin field 6b689eb2-48fd-4561-98c9-894692191f8a --><ul><li>Provide a written and verbal explanation of anogenital warts, their <a class=\"topic-reference internal-reference\" href=\"/topics/warts-anogenital/background-information/causes/\">causes</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/warts-anogenital/background-information/complications/\">complications</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/warts-anogenital/management/management/#available-treatments\">treatments</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/warts-anogenital/background-information/prognosis/\">prognosis</a>, for example the Family Planning Association (FPA) leaflet <a href=\"http://www.fpa.org.uk/sites/default/files/genital-warts-information-and-advice.pdf\" data-hyperlink-id=\"090fc64c-cdd6-43e6-871a-a98e014392be\">Genital warts</a>.</li><li>Explain how to use the treatment, and that several treatment attempts are normally required before the warts subside. For more information see the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/warts-anogenital/management/management/#how-to-use-imiquimod\">imiquimod</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/warts-anogenital/management/management/#how-to-use-podophyllotoxin\">podophyllotoxin</a>, and <a class=\"topic-reference internal-reference\" href=\"/topics/warts-anogenital/management/management/#how-to-use-sinecatechins\">sinecatechins</a>.</li><li>Inform the person that active treatments:<ul><li>May take 1–6 months to work.</li><li>Have significant failure rates.</li><li>Have significant relapse rates (because they do not eliminate the human papillomavirus).</li><li>Often involve discomfort and skin reactions.</li></ul></li><li>Advise women that no changes are recommended in the screening intervals of cervical cytology.</li><li>Recommend condom use and smoking cessation to improve response to treatment.<ul><li>However, explain that latex condoms may be weakened if in contact with imiquimod.</li></ul></li><li><ul></ul>If psychological distress is an issue, explain that psychological counselling is available.</li><li>If asked, reassure that the presence of anogenital warts does not always imply recent partner infidelity because human papillomavirus is thought to have a long latency period (3 weeks to 8 months).</li><li>Suggest that, with consent, the person's current sexual partner may benefit from assessment for undetected genital warts or other undetected sexually transmitted infections, or for explanation and advice about the disease process in their partner.</li></ul><!-- end field 6b689eb2-48fd-4561-98c9-894692191f8a --><!-- end item 63ed9def-1b0f-401f-b24e-5193382f1ba1 -->","subChapters":[{"id":"1b81b114-04f2-52e0-bf10-f4f8d61ea23c","slug":"how-to-use-imiquimod","fullItemName":"How to use imiquimod","depth":4,"htmlHeader":"<!-- begin field d633a694-aabb-47da-be43-a74d00c5b3b0 --><h4>What advice should I give someone using imiquimod?</h4><!-- end field d633a694-aabb-47da-be43-a74d00c5b3b0 -->","summary":null,"htmlStringContent":"<!-- begin item 824193b7-8c97-4053-a4a7-a74d00c5b1e5 --><!-- begin field 58579ad8-6a6e-43ae-bc53-a74d00c5b3b0 --><ul><li><strong>Advise anyone using imiquimod:</strong><ul><li>On how to apply the cream:<ul><li>A thin layer of imiquimod cream should be applied 3 times a week (for example Monday, Wednesday, and Friday; or Tuesday, Thursday, and Saturday) at bedtime and should remain on the skin for 6 to 10 hours. After this period, imiquimod cream should be washed off with mild soap and water. Treatment should continue until the clearance of visible genital or perianal warts, or for a maximum of 16 weeks per episode of warts.</li></ul></li><li>To avoid getting the cream on normal or broken skin and open wounds.</li><li>That hands should be washed thoroughly before and after applying the cream.</li><li>To avoid unprotected sexual contact soon after application because of a possible irritant effect on the partner.</li><li>That latex condoms may be weakened if in contact with imiquimod.</li><li>That response to treatment and adverse effects may be delayed by some weeks.</li><li>That inflammation may occur within a few applications of imiquimod (because the immune system has been stimulated rapidly).<ul><li>If this happens, they should stop applying the cream, allow the redness to subside, and then gradually reintroduce it once or twice a week.</li></ul></li><li>That permanent hypopigmentation and hyperpigmentation may occur.</li><li>To avoid applying excessive amounts of the cream and to follow the instructions for application carefully. Excess cream or prolonged contact with the skin may result in a severe reaction at the application site.</li></ul></li></ul><!-- end field 58579ad8-6a6e-43ae-bc53-a74d00c5b3b0 --><!-- end item 824193b7-8c97-4053-a4a7-a74d00c5b1e5 -->","subChapters":[]},{"id":"ef53b319-ac02-5da1-851a-aae7dd6aeccf","slug":"how-to-use-podophyllotoxin","fullItemName":"How to use podophyllotoxin","depth":4,"htmlHeader":"<!-- begin field a56c918f-0c85-49f7-98d1-a74d00c5ed14 --><h4>What advice should I give someone using podophyllotoxin?</h4><!-- end field a56c918f-0c85-49f7-98d1-a74d00c5ed14 -->","summary":null,"htmlStringContent":"<!-- begin item 1ac1434f-845a-4b08-bd13-a74d00c5eba1 --><!-- begin field 14708ad1-2d82-4eaf-a063-a74d00c5ed14 --><ul><li><strong>Advise anyone using podophyllotoxin:</strong><ul><li>On how to apply the cream:<ul><li>Podophyllotoxin cream should be applied twice a day for 3 consecutive days, followed by 4 days of no application. This should be repeated weekly, if necessary, for a maximum of four 3–day courses (maximum of five 3–day courses for Condyline<sup>®</sup>0.5% solution).</li></ul></li><li>To avoid getting the cream onto normal skin and open wounds.</li><li>To avoid unprotected sexual contact soon after application because of a possible irritant effect on the partner.</li><li>That podophyllotoxin can cause local irritation of the treated area. This may occur on the second or third day of application and decreases after treatment is discontinued. In most cases, the reactions are mild.</li><li>To discontinue treatment if there are significant adverse effects, such as soreness or ulceration.</li><li>To avoid applying excessive amounts of the cream and to follow the instructions for application carefully. Excessive application may cause severe systemic toxicity, including gastrointestinal, renal, haematological, and central nervous system effects.</li></ul></li></ul><!-- end field 14708ad1-2d82-4eaf-a063-a74d00c5ed14 --><!-- end item 1ac1434f-845a-4b08-bd13-a74d00c5eba1 -->","subChapters":[]},{"id":"e0e27ad8-adec-592d-baf6-2931bbd0eaa9","slug":"how-to-use-sinecatechins","fullItemName":"How to use sinecatechins","depth":4,"htmlHeader":"<!-- begin field efddba25-074c-4dc3-8841-a74e00f10327 --><h4>What advice should I give someone using sinecatechins?</h4><!-- end field efddba25-074c-4dc3-8841-a74e00f10327 -->","summary":null,"htmlStringContent":"<!-- begin item d1dc94da-e13a-49f0-8cf5-a74e00f103b1 --><!-- begin field 1f41218a-a730-46ce-a8b2-a74e00f10327 --><ul><li><strong>Advise anyone using s</strong><strong>inecatechins</strong><ul><li>On how to apply the ointment:<ul><li>A small amount of ointment (around a 0.5 cm strand) should be applied to each wart three times a day using the fingers. It should be dabbed on to ensure complete coverage, leaving a thin layer of ointment on the warts. A maximum of 250 mg in total should be used for all warts per single dose. It is not necessary to wash the ointment off prior to the next application.</li><li>Continue treatment until complete clearance of all warts, however, for no longer than 16 weeks in total, even if new warts develop during the treatment period.</li></ul></li><li>To avoid unprotected sexual contact soon after application because of a possible irritant effect on the partner.</li><li>To wash off the ointment before using condoms and vaginal diaphragms, as it may weaken them. </li><li>To avoid getting the ointment onto normal skin and open wounds.</li><li>That ointment can cause local irritation of the treated area, but this usually reduces after the first weeks of treatment.</li><li>To discontinue treatment if there are significant adverse effects, such as soreness or ulceration.</li><li>To avoid applying excessive amounts of the ointment and to follow the instructions for application carefully. </li></ul></li></ul><!-- end field 1f41218a-a730-46ce-a8b2-a74e00f10327 --><!-- end item d1dc94da-e13a-49f0-8cf5-a74e00f103b1 -->","subChapters":[]},{"id":"15e3dee8-69f2-532c-8574-05521ef08d56","slug":"basis-for-recommendation-6f7","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 7dc96bdc-78bf-48dd-bfbe-1300d1e87f99 --><h4>Basis for recommendation</h4><!-- end field 7dc96bdc-78bf-48dd-bfbe-1300d1e87f99 -->","summary":null,"htmlStringContent":"<!-- begin item 6f7de6ac-22b7-45df-8423-a5ef88bc7454 --><!-- begin field f1ff2cf0-a80f-4362-934f-62b98ee31f17 --><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK national guidelines on the management of anogenital warts </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BASHH, 2015</a>], joint recommendations on <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">RCGP, 2013</a>]<em>, </em>the <em>British Medical Journal</em> (BMJ) best practice guide <em>Genital warts </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BMJ Best Practice, 2016</a>] and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BNF 73, 2017</a>].</p><h5>Use of condoms</h5><ul><li>Consistent condom use has been shown to reduce the risk of acquisition of HPV infection and genital warts (a 30- 60% reduction) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BASHH, 2015</a>].<ul><li>They may reduce recurrence when both partners are infected, but the extent to which recurrence is due to re-infection is unknown.</li><li>Latex condoms may be weakened if in contact with imiquimod.</li></ul></li></ul><h5>How to use imiquimod</h5><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK national guidelines on the management of anogenital warts </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BASHH, 2015</a>] and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BNF 73, 2017</a>].</p><ul><li>Extending treatment with imiquimod to 20 weeks or beyond, in people who respond, is common practice but there is no evidence to support this [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BASHH, 2015</a>].</li></ul><h5>How to use podophyllotoxin</h5><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK national guidelines on the management of anogenital warts </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BASHH, 2015</a>] and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BNF 73, 2017</a>].</p><h5>How to use sinecatechins</h5><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK national guidelines on the management of anogenital warts </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BASHH, 2015</a>] and the Summary of Product Characteristics for Catephen 10% Ointment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">ABPI, 2015</a>].</p><!-- end field f1ff2cf0-a80f-4362-934f-62b98ee31f17 --><!-- end item 6f7de6ac-22b7-45df-8423-a5ef88bc7454 -->","subChapters":[]}]},{"id":"5550418f-0d72-59fe-b74d-81411dfebe75","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field 18c4875d-a2f7-41a3-87b3-b229d56cef5a --><h3>When should I refer someone with anogenital warts?</h3><!-- end field 18c4875d-a2f7-41a3-87b3-b229d56cef5a -->","summary":null,"htmlStringContent":"<!-- begin item 58f75d7c-5d51-4795-b166-d46355b46d65 --><!-- begin field b71d4e01-d21d-4afa-9c15-00b618978200 --><ul><li>If possible, refer all people with anogenital warts to a sexual health specialist.</li><li>Refer all people with ano-genital warts in the following situations:<ul><li>Diagnosis is uncertain.</li><li>Recurrent perianal warts.</li><li>Accompanying urinary symptoms (such as haematuria, or abnormal urine stream).</li><li>Suspected malignancy or intraepithelial neoplasia.</li><li>Immunosuppression, including HIV.</li><li>Present or suspected cervical, intrameatal, or intra-anal warts.</li><li>Pregnancy.</li><li>Children.</li><li>Elderly. </li></ul></li><li>Consider the possibility of sexual abuse in any child with anogenital warts, particularly if younger than 13 years of age. Follow appropriate child protection procedures and refer to a paediatrician if necessary. For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/warts-anogenital/management/management/#suspected-sexual-abuse\">suspected sexual abuse of a young person</a>.</li><li>Consider referral for counselling if the person has psychological distress.</li></ul><!-- end field b71d4e01-d21d-4afa-9c15-00b618978200 --><!-- end item 58f75d7c-5d51-4795-b166-d46355b46d65 -->","subChapters":[{"id":"5d83d30a-21cc-50b8-b4a2-128f41d68771","slug":"basis-for-recommendation-e4f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 2429bf5f-5744-435c-b969-49335dc7706a --><h4>Basis for recommendation</h4><!-- end field 2429bf5f-5744-435c-b969-49335dc7706a -->","summary":null,"htmlStringContent":"<!-- begin item e4fa3df2-8514-47e5-bed4-573be197d6c6 --><!-- begin field 5cdb7d2a-6161-483d-bee4-cd338920afc6 --><p>These recommendations are based on the British Association for Sexual Health (BASHH) and HIV <em>UK national guidelines on the management of anogenital warts </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BASHH, 2015</a>], joint recommendations on <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">RCGP, 2013</a>]<em>, </em>the <em>British Medical Journal</em> (BMJ) best practice guide <em>Genital warts </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BMJ Best Practice, 2016</a>], the National Institute of Health and Care Excellence (NICE) guideline <em>Child maltreatment: when to suspect maltreatment in under 18s </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">NICE, 2009a</a>], and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BNF for Children, 2017</a>].</p><!-- end field 5cdb7d2a-6161-483d-bee4-cd338920afc6 --><!-- end item e4fa3df2-8514-47e5-bed4-573be197d6c6 -->","subChapters":[]}]},{"id":"c4f654db-b760-55bb-a6f9-05c48a65f5b2","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field 75a36d4b-80a3-46bf-bd6e-a74d010d4e12 --><h3>What follow up is required for someone with anogenital warts?</h3><!-- end field 75a36d4b-80a3-46bf-bd6e-a74d010d4e12 -->","summary":null,"htmlStringContent":"<!-- begin item 2ce55f76-6aeb-44bb-819b-a74d010d4ca3 --><!-- begin field eb680871-9c93-4ad4-9569-a74d010d4e12 --><ul><li>Review the person after the completion of treatment to monitor its success, and to assess for further therapy.<ul><li>Change the treatment if the patient cannot tolerate the current treatment, or there is less than a 50% response to it by 4–5 weeks (8-12 weeks for imiquimod).</li></ul></li><li>If the person is concerned about recurrences, consider arranging a follow up 3 months after successful treatment, as this is when they are most likely to occur.</li><li>Arrange more frequent follow up in people who are immunocompromised. </li></ul><!-- end field eb680871-9c93-4ad4-9569-a74d010d4e12 --><!-- end item 2ce55f76-6aeb-44bb-819b-a74d010d4ca3 -->","subChapters":[{"id":"7ca1d04b-5662-5cea-aad2-3b3cf5ed5e57","slug":"basis-for-recommendation-1b0","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 9f79138b-5d5b-4210-a339-a74d010d4e12 --><h4>Basis for recommendation</h4><!-- end field 9f79138b-5d5b-4210-a339-a74d010d4e12 -->","summary":null,"htmlStringContent":"<!-- begin item 1b0a4617-e28f-4fee-976f-a74d010d4e12 --><!-- begin field eec7508b-e36d-4df6-8ccf-a74d010d4e12 --><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK national guidelines on the management of anogenital warts </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BASHH, 2015</a>], joint recommendations on <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">RCGP, 2013</a>], and the <em>British Medical Journal</em> (BMJ) best practice guide <em>Genital warts </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">BMJ Best Practice, 2016</a>].</p><!-- end field eec7508b-e36d-4df6-8ccf-a74d010d4e12 --><!-- end item 1b0a4617-e28f-4fee-976f-a74d010d4e12 -->","subChapters":[]}]},{"id":"3110e350-f12a-5455-9bb0-dc098f5826e1","slug":"suspected-sexual-abuse","fullItemName":"Suspected sexual abuse","depth":3,"htmlHeader":"<!-- begin field 500220e8-c52b-4b7d-becf-a75100c70fe5 --><h3>When should I suspect sexual abuse of a young person?</h3><!-- end field 500220e8-c52b-4b7d-becf-a75100c70fe5 -->","summary":null,"htmlStringContent":"<!-- begin item 5c1d1e7f-7c9e-4aab-958e-a75100c710a0 --><!-- begin field 6fae7711-23f3-47a5-983e-a75100c70fe5 --><ul><li>Although rare, consider the possibility of sexual abuse in any child or young person with anogenital warts, particularly in the following circumstances:<ul><li>The child is younger than 13 years of age, unless there is clear evidence of mother-to-child transmission during birth, or non-sexual transmission from a member of the household.</li><li>The young person is aged 13–15 years, unless there is clear evidence of mother-to-child transmission during birth, or non-sexual transmission from a member of the household, or that the infection was acquired from consensual sexual activity with a peer.</li><li>The young person is aged 16–17 years and there is no clear evidence of non-sexual transmission from a member of the household, or that the infection was acquired from consensual sexual activity <em>and </em>there is a clear difference in power or mental capacity between the young person and their sexual partner, in particular when the relationship is incestuous or with a person in a position of trust (such as a teacher, sports coach, minister of religion) <em>or </em>there is concern that the young person is being exploited.</li></ul></li><li>Follow appropriate child protection procedures and refer to a paediatrician if necessary.</li></ul><!-- end field 6fae7711-23f3-47a5-983e-a75100c70fe5 --><!-- end item 5c1d1e7f-7c9e-4aab-958e-a75100c710a0 -->","subChapters":[{"id":"ab879e17-1cd3-5a92-a9e2-0804a96665f3","slug":"basis-for-recommendation-db2","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 3affc34d-ed2f-4c8c-aaca-a75100c70fe9 --><h4>Basis for recommendation</h4><!-- end field 3affc34d-ed2f-4c8c-aaca-a75100c70fe9 -->","summary":null,"htmlStringContent":"<!-- begin item db2d870c-4cd1-46d8-b48f-a75100c70fe9 --><!-- begin field e4aaafaa-0596-41ac-befa-a75100c70fe9 --><p>These recommendations are based on the National Institute of Health and Care Excellence (NICE) guideline <em>Child maltreatment: when to suspect maltreatment in under 18s</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/warts-anogenital/references/\">NICE, 2009b</a>].</p><!-- end field e4aaafaa-0596-41ac-befa-a75100c70fe9 --><!-- end item db2d870c-4cd1-46d8-b48f-a75100c70fe9 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}